Steven R. Pacelli - 08 Mar 2022 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Managing Dir., Dexcom Ventures
Signature
By: Jereme Sylvain For: Steven R Pacelli
Issuer symbol
DXCM
Transactions as of
08 Mar 2022
Transactions value $
-$1,392,363
Form type
4
Date filed
10 Mar 2022, 18:27
Previous filing
24 Feb 2022
Next filing
24 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award $4.98 +4.98K +14.5% $0.00* 39.4K 08 Mar 2022 Direct F1, F2
transaction DXCM Common Stock Disposed to Issuer -$535K -1.32K -3.35% $406.06 38K 09 Mar 2022 Direct F2, F3
transaction DXCM Common Stock Disposed to Issuer -$378K -932 -2.45% $406.06 37.1K 09 Mar 2022 Direct F2, F3
transaction DXCM Common Stock Disposed to Issuer -$479K -1.18K -3.18% $406.06 35.9K 09 Mar 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2 Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023.
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.